Physician profile

Matthew Smith

Pulmonary Disease · Largo, FL

NPI 1588688543

$6,373.17

in general payments reported to CMS, 2019-2025

23 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $1,796.22 2019-2022
Astrazeneca Pharmaceuticals Lp $1,482.36 2019-2022
Boehringer Ingelheim Pharmaceuticals, INC. $685.35 2019-2022
Mylan Specialty L.P. $553.59 2019-2022
Sunovion Pharmaceuticals INC. $286.17 2019-2020
Jazz Pharmaceuticals INC. $224.70 2019-2021
Regeneron Healthcare Solutions, INC. $211.07 2019-2022
Teva Pharmaceuticals USA, INC. $204.06 2019-2022
United Therapeutics Corporation $137.65 2019-2021
Genentech USA, INC. $112.19 2019-2022
Novartis Pharmaceuticals Corporation $96.73 2019-2022
Amgen INC. $86.29 2021-2022
Harmony Biosciences LLC $65.06 2020
Vapotherm INC $64.96 2022
Bayer Healthcare Pharmaceuticals INC. $64.90 2019
Show all 23 companies
CompanyGeneral paymentsYearsTop products
Genzyme Corporation $58.95 2019-2022
Insmed, INC. $57.61 2019-2022
Covis Pharma Gmbh $48.89 2022
Eisai INC. $44.69 2021-2022
Baxter Healthcare $43.67 2022
Inogen, INC. $22.65 2022
Nabriva Therapeutics, Plc $12.93 2020
Circassia INC. $12.48 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Matthew Smith

$6,373.17

in general payments reported 2019-2025

Years
2019-2022
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/207548/matthew-smith

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.